Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
MA02 - RET and Novel Combinations of Osimertinib
- 09:30 - 10:30
- 9/08/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Novel Therapeutics and Targeted Therapies
-
+
MA02.02 - Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer
09:35 - 09:40 | Presenter: Qing Zhou
- Abstract
Loading...
-
+
FP16 - Tumor Biology and Systems Biology: Basic and Translational Science
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters (Featured)
- Track: Tumor Biology and Systems Biology: Basic and Translational Science
-
+
FP16.03 - Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial
00:00 - 00:00 | Presenter: Myung-Ju Ahn
- Abstract
Loading...
-
+
P01 - Early Stage/Localized Disease/Ablative Therapies - Adjuvant Therapy
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Early Stage/Localized Disease/Ablative Therapies
-
+
P01.01 - LIBRETTO-432: A Placebo-Controlled Phase 3 Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC
00:00 - 00:00 | Presenter: Jonathan Goldman
- Abstract
Loading...
-
+
P40 - Multimodality of Advanced Lung Cancer - Clinical Outcomes
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Multimodality of Advanced Lung Cancer
-
+
P40.02 - Pemetrexed in Advanced-stage Lymphoepithelioma Carcinoma of Lung
00:00 - 00:00 | Presenter: Ri-Qiang Liao
- Abstract
Loading...
-
+
P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P45.06 - Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer
00:00 - 00:00 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
P45.08 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading...
-
+
P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P47.09 - Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
00:00 - 00:00 | Presenter: Christophe Dooms
- Abstract
Loading...
-
+
P49 - Novel Therapeutics and Targeted Therapies - EGFR Major
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P49.01 - Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC
00:00 - 00:00 | Presenter: Song Dong
- Abstract
Loading...
-
+
P51 - Novel Therapeutics and Targeted Therapies - EGFR Resistance
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P51.01 - Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
00:00 - 00:00 | Presenter: Chong Kin Liam
- Abstract
Loading...
-
+
P52 - Novel Therapeutics and Targeted Therapies - KRAS
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P52.02 - High SHP2 Expression Determines the Efficacy of PD-1/PD-L1 Inhibitors in Advanced KRAS Mutant Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Hui-Bo Feng
- Abstract
Loading...
-
+
IS04 - Industry Symposium Sponsored by Astrazeneca: Redefining the Treatment Journey in NSCLC with Immuno-oncology and EGFR-TKIs
- 05:15 - 06:15
- 9/09/2021
- Location: Industry Symposium Auditorium via Industry Hub
- Not for CME Credit
- Type: Industry Supported Symposium
- Track: N.A.
-
+
IS04.01 - Welcome and Introduction
05:15 - 05:20 | Presenter: Yi-Long Wu
- Abstract
No abstract available for this presentation
